BioSpace News Archive

The Braxia clinic is situated within a 14,000 square foot multi-disciplinary state of the art facility, and marks Braxia’s fourth clinic in Canada, expanding its operations nationally.

- Fast Track Designation for GEM103 in dry AMD granted January 2021 - GEM103 Phase 2a study in geographic atrophy data on track for June 2021 - GEM103 Phase 2a as a possible add-on therapy for patients with wet AMD at risk for macular atrophy completed enrollment, with six-month data to be shared by year-end - GEM103 preclinical data presentation demonstrating potential for differentiated safety profile

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the first quarter ended March 31, 2021.

Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced the completion of enrollment in its Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor

The provider-led partnership with Medically Home will transform the delivery of acute-level care for patients with serious or complex illnesses.

Over the years, there has been rise in numbers of ostomy carriers, or stomata or stoma as these are variously called, the structures that are attached to hollow organs after ostomy surgeries.